The U.S. House of Representatives introduced the Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act of 2025. The legislation would reauthorize the National Breast and Cervical Cancer Early Detection Program for fiscal years 2026 through 2030.
Des Moines, Iowa – “Iowa has the 2nd highest cancer rates in the country and our cancer rates continue to rise year over year. The State Legislature’s votes to cut Medicaid expansion will plunge our state deeper into this cancer crisis.
BISMARCK, N.D. – The North Dakota Senate on Monday passed House Bill 1216 on a 30-14 vote, setting aside a “Do Not Pass” by the Senate Human Services Committee and sending the bill back to Senate Appropriations for review and approval of amendments.
Yesterday, both chambers in the New Jersey State Legislature passed legislation (Assembly Bill 4163 / Senate Bill 3098) to increase access to biomarker testing, which can help determine the best treatment plan for each patient. The bill will now go to Governor Murphy’s desk, providing him the opportunity to ensure coverage of this essential testing for more New Jerseyans. The American Cancer Society Cancer Action Network (ACS CAN) is leading the efforts on this significant policy change to ensure more patients can get the testing needed to access precision medicine.
BISMARCK, N.D. –– House Bill 1283 was given a 4-1 Do Not Pass by the North Dakota Senate Business and Industry Committee on Monday following passage in the House. The bill would put North Dakotans one step closer to the peace of mind they need when it comes to breast cancer diagnostics.
The American Cancer Society Cancer Action Network (ACS CAN) united cancer survivors, patients and caregivers from across Nevada at the state capitol for ‘Cancer Action Day,’ Monday to urge lawmakers to oppose AB76, which is currently being considered by the state legislature. If enacted, the bill would allow for indoor cannabis smoking and weaken the Nevada Clean Indoor Air Act.
A new report by the American Cancer Society Cancer Action Network (ACS CAN) found that over 70% of commercially-insured patients had out-of-pocket costs for follow-up breast cancer diagnostic tests in 2023.
Insurance coverage of biomarker testing will reduce health disparities for cancer patients & improve outcomes across broad spectrum of serious disease